Supreme Court Clarifies Induced Infringement Standard in Hikma v. Amarin Skinny Label Case

The U.S. Supreme Court unanimously ruled on June 4, 2026, in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., No. 24-889, that induced patent infringement under 35 U.S.C. § 271(b) requires a plaintiff to plausibly allege that the defendant took affirmative steps to encourage infringement. The Court held that passive statements that recipients merely could read as instructions to infringe are not sufficient, rejecting the Federal Circuit's focus on whether medical providers could interpret a generic manufacturer's statements as encouraging off-label use. The decision reversed the Federal Circuit and reinstated the district court's dismissal of Amarin's complaint.

The case arose under the Hatch-Waxman Act's "skinny label" pathway. Amarin markets Vascepa (icosapent ethyl), an omega-3 fatty acid approved by the FDA in 2012 for severe hypertriglyceridemia and in 2019 for reducing cardiovascular risk in certain patients, with the CV use protected by method-of-use patents. Hikma obtained FDA approval for a generic version using a Section VIII skinny label limited to the unpatented severe hypertriglyceridemia indication, and the generic received an "AB" therapeutic-equivalence rating. Amarin sued, alleging that Hikma's label, patient information leaflet, website, and press releases—including references to "generic Vascepa"—induced physicians to prescribe the generic for the patented CV use. The district court dismissed the complaint; the Federal Circuit reversed; the Supreme Court again reversed.

The Court clarified the "active steps" requirement for inducement liability, distinguishing statements designed to encourage infringement from statements that merely permit an inference of encouragement. Only the former can support liability. Foreseeable off-label use, even if expected, is insufficient. The Court drew on its recent decision in Cox Communications, Inc. v. Sony Music Entertainment, emphasizing that the absence of express promotion or marketing directed to the infringing use weighs against inducement liability. Inducement may still be implicit, but implicit encouragement must be clear to the relevant audience and affirmative in nature.

The Court rejected several categories of allegations common in skinny-label cases. Conduct required by regulatory law or consistent with standard industry practice—such as label mirroring subject to the carve-out or referring to a product as a generic equivalent—cannot form the basis for inducement liability. Omissions or silence, including the failure to restate limitations on use or disclaim patented indications, are not affirmative conduct. Vague or indirect statements, particularly when paired with speculation about how medical providers might respond, are insufficient.

The ruling is expected to shape how induced infringement claims are evaluated in cases involving technologies far beyond pharmaceuticals, including software and medical devices. The Court's alignment of patent law with copyright and antitrust pleading standards provides guidance for practitioners. For generic manufacturers, the decision provides clarity that regulatory compliance and standard commercial practices are not actionable, while leaving open liability where a manufacturer engages in affirmative promotional conduct directed at the patented use. For brand manufacturers, it substantially raises the bar for pleading and proving inducement.

The reasoning also extends to functional foods, wellness beverages, dietary supplements, and other innovative food and beverage products working around method-of-use patent landscapes. Under the Hikma standard, a company that deliberately avoids promoting a patented use has stronger grounds to defeat an inducement allegation at the pleading stage by keeping labels, marketing copy, website claims, influencer materials, and sales training focused on non-patented structure/function claims or dietary guidance. The decision does not create a statutory carve-out for foods or beverages and leaves untouched claims based on direct infringement, contributory infringement, or composition of matter. It addressed only the sufficiency of a complaint at the pleading stage, so discovery may still reveal evidence of active encouragement not apparent from public-facing materials alone.